CSF2 and glioblastoma: Currently, clinical trials using TLR3 agonists in combination with GM-CSF (ClinicalTrials.gov Identifier: NCT02149225) or peptide vaccine (ClinicalTrials.gov Identifier: NCT01920191) for treatment of GBM are being initiated.